相关实验视频

Updated: Jul 1, 2025

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Published on: August 14, 2019

来自L. Tephrosia purpurea的多个支气管扩展活性通路的新型黄类药物. (个人) (个人) 在沙特阿拉伯不断增长

Maged S Abdel-Kader^1,2, Abdulaziz S Saeedan³, Najeeb U Rehman³

¹Department of Pharmacognosy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Kingdom of Saudi Arabia.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

|March 4, 2024

概括

铁紫全提取物 (TPTE) 和其成份显示出支气管扩展作用. 他们分离了7种活性黄,其中4种新化合物表现出类似于帕帕维林和类似于迪西克洛的抗支气管的活性.

科学领域:

药理学药理学是指药理学的学科.
自然产品化学化学
呼吸系统医学呼吸系统医学

背景情况:

紫色 (T. purpurea) 是一种具有潜在呼吸系统益处的药用植物.
了解其支气管扩展活性的特定化合物对于治疗开发至关重要.

研究的目的:

从T. purpurea中分离和描述具有支气管扩展性能的活性化合物.
研究这些孤立化合物的作用机制.
评估提取物和分离化合物的体内疗效,以防止诱导的支气管.

主要方法:

紫素全提取物 (TPTE) 的液体-液体分化.
使用几内亚猪气管肌肉制剂进行活体生物试验引导的活性化合物的分离.
使用光谱技术 (NMR,MS,光学旋转,CD) 阐明结构.
在体外测试以确定对卡巴霍尔 (CCh) 和高 (K+) 诱导的收缩的抑制作用.
在体内评估对海豚中抗胰岛素诱导的支气管的保护.

主要成果:

TPTE的甲基部分表现出显著的活体支气管扩展活性.
他们分离了七种活性黄,包括四种新型化合物:epi-Tephroapollin G (1),Acetyltephroapollin C (3),4''-Dehydroxytephroapollin E (4) 和epi-Tephroapollin F (5).
化合物1,3,4和兰西欧拉丁A (6) 抑制了CCH和K+诱导的收缩,表明双化酶和Ca++抑制作用.
化合物5和7是CCH诱导的收缩的强有力的抑制剂,类似于dicyclomine.
化合物2,5和7表现出选择性肌肉蛋白受体阻塞.
口服TPTE,其粉碎片及其化合物7可在体内显著保护抗胰岛素诱导的支气管.

结论:

紫色含有强大的支气管扩展化合物,主要是黄.
隔离的化合物表现出多种作用机制,包括固酶抑制,Ca++通道阻塞和肌肉蛋白受体对抗作用.
这些发现支持T. purpurea用于呼吸系统疾病的传统用途,并强调其作为新型抗喘药物的来源的潜力.

关键词:

支气管扩展剂是一种支气管扩展剂.这是一种Epi-Tephroapollin.这是ex-vivo.几内亚猪几内亚猪是什么意思在生物体内.在Tefropurpugazanin中使用.铁酸紫色素的化.

更多相关视频

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Agonists: Mixed-Action Agents

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...